109 related articles for article (PubMed ID: 38862718)
1. Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.
von Maltzahn R; Mayo MJ; Smith HT; Thompson A; Das S; de Souza AR; Lisi E; Levy C; McLaughlin MM; Jones D
J Patient Rep Outcomes; 2024 Jun; 8(1):60. PubMed ID: 38862718
[TBL] [Abstract][Full Text] [Related]
2. GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
Levy C; Kendrick S; Bowlus CL; Tanaka A; Jones D; Kremer AE; Mayo MJ; Haque N; von Maltzahn R; Allinder M; Swift B; McLaughlin MM; Hirschfield GM;
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1902-1912.e13. PubMed ID: 36343847
[TBL] [Abstract][Full Text] [Related]
3. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
[TBL] [Abstract][Full Text] [Related]
4. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
[TBL] [Abstract][Full Text] [Related]
5. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
6. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
Kremer AE; Mayo MJ; Hirschfield G; Levy C; Bowlus CL; Jones DE; Steinberg A; McWherter CA; Choi YJ
Liver Int; 2022 Jan; 42(1):112-123. PubMed ID: 34403559
[TBL] [Abstract][Full Text] [Related]
7. Population Dose-Response-Time Analysis of Itch Reduction and Patient-Reported Tolerability Supports Phase III Dose Selection for Linerixibat.
Carreño F; Karatza E; Mehta R; Collins J; Austin D; Swift B
Clin Pharmacol Ther; 2024 Feb; 115(2):288-298. PubMed ID: 37953500
[TBL] [Abstract][Full Text] [Related]
8. Japanese subgroup analysis of GLIMMER: A global Phase IIb study of linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.
Tanaka A; Atsukawa M; Tsuji K; Notsumata K; Suyama A; Ito H; Das S; von Maltzahn R; McLaughlin MM
Hepatol Res; 2023 Jul; 53(7):629-640. PubMed ID: 36852705
[TBL] [Abstract][Full Text] [Related]
9. Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat.
Karatza E; Swift B; Carreño F; Mukherjee S; Casillas L; Lennie J; Fettiplace J; McLaughlin MM; Kremer AE
Liver Int; 2024 May; ():. PubMed ID: 38780109
[TBL] [Abstract][Full Text] [Related]
10. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
11. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
[TBL] [Abstract][Full Text] [Related]
12. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
Yagi M; Tanaka A; Namisaki T; Takahashi A; Abe M; Honda A; Matsuzaki Y; Ohira H; Yoshiji H; Takikawa H;
J Gastroenterol; 2018 Oct; 53(10):1151-1158. PubMed ID: 29663077
[TBL] [Abstract][Full Text] [Related]
13. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV; Bowlus CL; Levy C; Akarca US; Alvares-da-Silva MR; Andreone P; Arrese M; Corpechot C; Francque SM; Heneghan MA; Invernizzi P; Jones D; Kruger FC; Lawitz E; Mayo MJ; Shiffman ML; Swain MG; Valera JM; Vargas V; Vierling JM; Villamil A; Addy C; Dietrich J; Germain JM; Mazain S; Rafailovic D; Taddé B; Miller B; Shu J; Zein CO; Schattenberg JM; ;
N Engl J Med; 2024 Feb; 390(9):795-805. PubMed ID: 37962077
[TBL] [Abstract][Full Text] [Related]
15. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
[TBL] [Abstract][Full Text] [Related]
16. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis.
Turner IB; Rawlins MD; Wood P; James OF
Aliment Pharmacol Ther; 1994 Jun; 8(3):337-42. PubMed ID: 7918930
[TBL] [Abstract][Full Text] [Related]
17. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.
Bolier R; de Vries ES; Parés A; Helder J; Kemper EM; Zwinderman K; Elferink RPO; Beuers U;
Trials; 2017 May; 18(1):230. PubMed ID: 28535810
[TBL] [Abstract][Full Text] [Related]
18. Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials.
Soung J; Ständer S; Gutermuth J; Pau-Charles I; Dawson Z; Yang FE; Sun L; Pierce E; Elmaraghy H; Stein-Gold L
J Dermatolog Treat; 2024 Dec; 35(1):2329240. PubMed ID: 38679419
[TBL] [Abstract][Full Text] [Related]
19. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
